The Navicor Group: 2017
The Navicor Group LLC
480 Olde Worthington Road
Suite 202
Westerville, OH 43082
Ten Penn Center
1801 Market Street
27th Floor, Suite 2700
Philadelphia, PA 19103
Telephone: 614-543-6011
E-mail: [email protected]
Website: the.oncology.agency
Winner
Agency of the Year, Category III
Accounts
Account wins 9
Active business clients 14
Brands by 2016 sales
Brand-product accounts held 28
$25 million or less 1
$25 million to $50 million 2
$50 million to $100 million 2
$100 million to $500 million 2
$500 million to $1 billion 2
$1 billion or more 2
Products yet to be approved/launched 10
Services Mix
Product promotion 35%
Digital 25%
Disease awareness 20%
Branding 10%
Conventions 10%
Client Roster
Aimmune
AMAG
Celgene
Incyte
Lexicon
Loxo Oncology
Mallinckrodt
Mallinckrodt Pharmaceuticals/Cadence Pharmaceuticals
Millennium: The Takeda Oncology Company
Multiple Myeloma Foundation
Myriad Genetics
OncoGenex
OSUCCC – James
R-Pharm US
Seattle Genetics
Sunesis
Tesaro
2016 marked another amazing year of growth for Navicor, an inVenitv Health company, according to agency management. Now in its 12th year, the oncology-focused agency saw more than 5o percent financial growth over 2015 and increased its head count from 74 to 107 employees across two office locations.
The Year’s Accomplishments
For a third consecutive year, Navicor achieved a new business win rate of more than 50 percent, executives say, adding eight new clients. As a result, Navicor expanded its office space in Ten Penn Center in Philadelphia in July.
“We have successfully helped over a dozen companies with their first commercialization,” explains Marvin Bowe, executive creative director, managing director, of the Philadelphia office. “Because of our thorough knowledge of oncology and understanding of OPDP submissions for both traditional and accelerated filings, 15 companies in the pre-approval stage have approached Navicor for our expertise.”
According to Dave Querry, president, “The complex world of oncology demands more than a passing interest. Success requires commitment, a depth of understanding, and a balance between science and art to create communications that both inform and inspire action.”
In 2016, Navicor expanded with several key accounts. These accounts included developing disease education and trial awareness programs for an emerging drug developer in the infantile fibrosarcoma market. The agency partnered on a portfolio of three new brand launches for an existing large pharma client, while also creating a new campaign for their lead pain management asset. For another emerging biopharmaceutical client, Navicor was honored to be engaged for the global launch of a novel PARP inhibitor in the ovarian cancer segment. New business added to Navicor’s roster included clients across the autoimmunology segment, a portfolio of global brands in the US myeloma and lymphoma categories, and a breast cancer prognostic.
Structures & Services
Navicor’s success continues to be led by Querry, with Bowe overseeing the Philadelphia office and Rich D’Ginto assuming the executive creative director, managing director role for the Columbus office. With all the growth, the Navicor team added 33 new members. Among those added were several leadership positions, including David Raube, VP creative director; Michele Zwiebel, VP, creative director; Carolyn Holloway, VP, resource management; Paul “P.J.” Zimmer, VP, digital strategy and innovation director; and Barry Vucsko, VP, account director.
Future Plans
For 2017, Navicor plans to continue the agency’s path of global expansion and broader integrated solutions. One key area of focus is to “open up greater opportunity to collaborate with our inVentiv partners in medical communications and public relations to extend reach and expand capabilities for our clients’ brands beyond marketing and advertising,” Querry says. Navicor additionally plans to expand its Philadelphia offices during the second quarter of 2017.
Philanthropy/Citizenship
At Navicor, cancer is more than a therapeutic category – it’s personal, agency management says. As D’Ginto explains, “Our specialized knowledge and experience is your key to success in the oncology market, but we always remember that improving patient outcomes is the ultimate goal.”
During 2016, Navicor supported The Leukemia & Lymphoma Society, Pancreatic Cancer Action Network, and St. Jude Children’s Research Hospital through a variety of team-building activities including runs, walks, and social events raising almost $10,000 to fund research.
